Rates of Inhibitor development in previously untreated patients with severe hemophilia A treated with plasma-derived or recombinant factor VIII: no proof of difference or proof of no difference?
Semin Thromb Hemost
.
2014 Mar;40(2):269-70.
doi: 10.1055/s-0034-1367471.
Epub 2014 Feb 5.
Authors
Andrea Messori
1
,
Valeria Fadda
1
,
Dario Maratea
1
,
Sabrina Trippoli
1
Affiliation
1
HTA Unit, ESTAV Toscana Centro, Regional Health Service, Firenze, Italy.
PMID:
24500575
DOI:
10.1055/s-0034-1367471
No abstract available
Publication types
Letter
Comment
MeSH terms
Factor VIII / adverse effects*
Hemophilia A / drug therapy*
Humans
Substances
Factor VIII